Medarex - 500 Beiträge pro Seite

[Elbabo]

Hier die Zahlen von Medarex, schaun nicht sehr gut aus. Kann mir jemand sagen wie die Analystenschätzungen waren.

Medarex erreichte demnach bei einem Umsatz von 3,109 Millionen US$ im zweiten Quartal 2000 einen Verlust von 5,554 Millionen US$ oder $ 0,16/Aktie. Im Jahr zuvor lag das Ergebnis bei einem Umsatz von noch 1,433 Millionen US$ bei 4,430 Millionen US$ oder $ 0,14/Aktie. Im ersten Halbjahr 2000 lag der Umsatz bei 5,242 Millionen US$ und der Verlust bei 9,879 Millionen US$ oder $ 0,28/Aktie. Im Vorjahr erreichte man bei einem Umsatz von noch 7,027 Millionen US$ einen Verlust von 5,359 Millionen US$ oder $ 0,17/Aktie.(Aus dem Juchu-weekly)

[BFBR]

Die Zahlen sind schon "Schnee von gestern" und wurden am 10.08. veröffentlicht. Der Verlust war infolge von hohen Forschungsaufwendungen höher als vom Markt erwartet.

[money_max]

Ein "positiv engulfing pattern". Dies ist ein Kaufsignal, wenn man der Charttechnik glauben darf.

Wir werden sehen.

money_max

[lilabaer]

da ich auch investiert bin: Augen zu und durch. Aber im Ernst, ich glaube das Tal haben wir überschritten, auch wenn es wieder mal Tiefschläge gibt, langfristig zeigt die Tendenz nach oben.

[Mr.Atta]

Schaut euch doch mal den Tageschart von Medarex an.
So etwas habe ich bei Medarex noch nicht gesehen.
Glaubt ihr die 91 Dollar Linie hat etwas zu sagen?

[IWA Japan]

also die höheren Verluste sind ausschießlic hauch höhere R+D Kosten zurückzuführen, dass kann man auch locker postiv interpretieren :d

je mehr jetzt geforscht wird, desto besser werden die Produkte und umso höher später der Umsatz

[IWA Japan]

Medarex and Athersys Announce Collaboration To Develop Human Antibody Therapeutics
PRINCETON, N.J. and CLEVELAND, Aug. 16 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) and Athersys, Inc. announced today a collaboration to develop novel therapeutics produced through the joint application of Medarex`s HuMAb-Mouse® technology and Athersys` RAGE technology. The two companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics. Athersys will apply its expertise in proteomics and expects to contribute 10 or more disease-related targets to the collaboration. These targets are expected to be in the fields of cancer and other life-threatening or debilitating diseases.

Under the terms of the collaboration, Medarex and Athersys have agreed to share preclinical and clinical responsibilities, and the two companies intend to jointly commercialize products resulting from the research program. Additionally, Athersys has acquired an option to obtain access to Medarex`s HuMAb technology for targets that are outside the collaboration and Medarex has acquired an option to obtain access to validated therapeutic targets produced with Athersys` proprietary RAGE-VT(TM) technology and has also made an equity investment in Athersys.

``We are pleased to expand our `Applied Genomics` product development program through this partnership with Athersys. The combination of Athersys` proteomics expertise with our human antibody technology is a logical match for the efficient development of new therapeutics,`` said Donald L. Drakeman, President and CEO of Medarex.

``The RAGE technology has powerful utility in the generation of therapeutic targets which is greatly complemented by the HuMAb-Mouse technology, as well as Medarex`s other capabilities, including their fully validated manufacturing system,`` said Dr. Gil Van Bokkelen, President and CEO of Athersys. ``This strategic partnership combines Medarex`s strengths with two distinct facets of the RAGE technology, its powerful utility in the area of functional genomics, and its use as an alternative system for production of cell lines expressing validated biological targets without requiring the physical cloning and isolation of specific genes.``

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse and TC Mouse(TM) systems for the creation of high-affinity, fully human antibodies; T-12 Development(SM) offering the capability of moving from target to trial in approximately 12 months; and Trans-Phage Technology(SM) combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at www.medarex.com .

Athersys is engaged in the development of therapeutic products for the treatment of significant and life threatening diseases. Athersys` research and development programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expression)(TM) and the SMC (Synthetic Microchromosome)(TM) vector system. By applying the RAGE technology, Athersys can rapidly generate validated biological targets for drug development or related applications, conduct high throughput functional screening on a genome wide basis for novel genes and proteins, and commercially produce specific therapeutic proteins. This press release and further information on Athersys can be found at: www.Athersys.com .

For Medarex: Except for the historical information presented herein, certain matters discussed in this press release are forward-looking statements that are subject to unknown risks and uncertainties. These risks and uncertainties include, but are not limited to, Medarex`s early stage of product development, history of operating losses and accumulated deficit, dependence on strategic alliances, government regulation of the biopharmaceutical industry and other risks that may be detailed from time to time in Medarex`s periodic reports and registration statements filed with the Securities and Exchange Commission.

For Athersys: Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of Athersys` proposed products (such as marketing, safety, regulatory, patent or product liability, supply, competition and other risks).

SOURCE: Medarex, Inc.


IWA

[money_max]

Medarex und Athersys verkünden Zusammenarbeit, um menschliche
Antikörpertherapeutik zu entwickeln

Medarex and Athersys Announce Collaboration To Develop Human Antibody Therapeutics
PRINCETON, N.J. and CLEVELAND, Aug. 16 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX - news) and Athersys, Inc. announced today a collaboration to develop novel therapeutics produced through the joint application of Medarex`s HuMAb-Mouse® technology and Athersys` RAGE technology. The two companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics. Athersys will apply its expertise in proteomics and expects to contribute 10 or more disease-related targets to the collaboration. These targets are expected to be in the fields of cancer and other life-threatening or debilitating diseases.

Under the terms of the collaboration, Medarex and Athersys have agreed to share preclinical and clinical responsibilities, and the two companies intend to jointly commercialize products resulting from the research program. Additionally, Athersys has acquired an option to obtain access to Medarex`s HuMAb technology for targets that are outside the collaboration and Medarex has acquired an option to obtain access to validated therapeutic targets produced with Athersys` proprietary RAGE-VT(TM) technology and has also made an equity investment in Athersys.

``We are pleased to expand our `Applied Genomics` product development program through this partnership with Athersys. The combination of Athersys` proteomics expertise with our human antibody technology is a logical match for the efficient development of new therapeutics,`` said Donald L. Drakeman, President and CEO of Medarex.

``The RAGE technology has powerful utility in the generation of therapeutic targets which is greatly complemented by the HuMAb-Mouse technology, as well as Medarex`s other capabilities, including their fully validated manufacturing system,`` said Dr. Gil Van Bokkelen, President and CEO of Athersys. ``This strategic partnership combines Medarex`s strengths with two distinct facets of the RAGE technology, its powerful utility in the area of functional genomics, and its use as an alternative system for production of cell lines expressing validated biological targets without requiring the physical cloning and isolation of specific genes.``

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse and TC Mouse(TM) systems for the creation of high-affinity, fully human antibodies; T-12 Development(SM) offering the capability of moving from target to trial in approximately 12 months; and Trans-Phage Technology(SM) combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at www.medarex.com .

Athersys is engaged in the development of therapeutic products for the treatment of significant and life threatening diseases. Athersys` research and development programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expression)(TM) and the SMC (Synthetic Microchromosome)(TM) vector system. By applying the RAGE technology, Athersys can rapidly generate validated biological targets for drug development or related applications, conduct high throughput functional screening on a genome wide basis for novel genes and proteins, and commercially produce specific therapeutic proteins. This press release and further information on Athersys can be found at: www.Athersys.com .

For Medarex: Except for the historical information presented herein, certain matters discussed in this press release are forward-looking statements that are subject to unknown risks and uncertainties. These risks and uncertainties include, but are not limited to, Medarex`s early stage of product development, history of operating losses and accumulated deficit, dependence on strategic alliances, government regulation of the biopharmaceutical industry and other risks that may be detailed from time to time in Medarex`s periodic reports and registration statements filed with the Securities and Exchange Commission.

For Athersys: Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of Athersys` proposed products (such as marketing, safety, regulatory, patent or product liability, supply, competition and other risks).

SOURCE: Medarex, Inc.

Beide Unternehmen wollen gemeinsam menschliche Antikörper als
Therapeutik erforschen, entwickeln und vermarkten. Außerdem erhalten die Firmen Zugriff auf die Technologie des anderen.


RAGE-Technologie von athersys


Klingt doch ganz gut

money_max

[money_max]

Schade, wieder zu langsam

[b.frötsch]

besser 2 mal als kein mal der wille zählt

mfg
b.frötsch

[Elbabo]

Beim Chart bringts noch nicht allzuviel!!!

[IWA Japan]

würde davon auch kurzfrsitg nicht zu viel wegen der MEdlung erwarte.

Sie hat aber grundsätzlichen Charakter, womit mittelfristig die Postion von MEDX immer besser wird

[money_max]

und das sagt juchu zum Deal von gestern:

Medarex (MEDX) gab eine Kooperation zur Entwicklung neuer Therapeutika mit Ahtersys bekannt.

Dabei sollen diese durch die gemeinsame Verwendung der HuMAb-Mouse Technologie von Medarex und der RAGE Technologie von Athersys produziert werden.

Im Rahmen dieser Kooperation sollen vollständige menschliche Antikörper als Therapeutika entwickelt und ansschließend auch vermarktet werden.

Ahtersys kann dabei sein Wissen im Bereich der Proteomics beisteuern und zusätzlich 10 oder mehr Targets einbringen.

Finanzielle Details zu diesem Deal wurden bislang nicht veröffentlicht.

Aktueller Kurs von Medarex: $ ~92,-- (+ 1,38%)

FAZIT: Wir sind der Meinung, dass es sich bei diesem Deal um eine ideal Ergänzung handelt und sind davon überzeigt, dass BEIDE Unternehmen von den Synergieeffekten auf kurz oder lang profitieren werden können. Bis Ende des Jahres erwarten wir uns bei Medarex Kurse bis zu $ 120,--.